title: A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
abstract: African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).
authors.affiliation: Institute for Animal Health, Pirbright, Woking, Surrey, United Kingdom. javier.castillo-olivares@bbsrc.ac.uk
authors.forename: Javier
authors.initials: J
authors.lastname: Castillo-Olivares
authors.forename: Eva
authors.initials: E
authors.lastname: Calvo-Pinilla
authors.forename: Isabel
authors.initials: I
authors.lastname: Casanova
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Bachanek-Bankowska
authors.forename: Rachael
authors.initials: R
authors.lastname: Chiam
authors.forename: Sushila
authors.initials: S
authors.lastname: Maan
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Nieto
authors.forename: Javier
authors.initials: J
authors.lastname: Ortego
authors.forename: Peter Paul Clement
authors.initials: PP
authors.lastname: Mertens
mesh_terms: D000355:African Horse Sickness / Q000517:prevention & control* / Q000628:therapy; D000356:African Horse Sickness Virus / Q000235:genetics* / Q000276:immunology; D000818:Animals; D036022:Capsid Proteins / Q000235:genetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005822:Genetic Vectors / Q000627:therapeutic use*; D006736:Horses; D051379:Mice; D053633:Receptor, Interferon alpha-beta / Q000172:deficiency / Q000235:genetics*; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D036022:Capsid Proteins; C508032:Ifnar1 protein, mouse; C442519:VP2 protein, African horse sickness virus; D014614:Vaccines, Synthetic; D053633:Receptor, Interferon alpha-beta